By David D’Souza, August 27, 2026
What if the answer to Canada’s safe-supply debate isn’t an outright ban or unfettered access, but smarter, more targeted use for those at greatest risk — and better access to treatment and recovery?
Canada’s illicit‑drug supply has changed dramatically since many of our standard addiction treatments were developed. Fentanyl and increasingly potent analogues (such as fluorofentanyl, methylfentanyl, and carfentanil) have made the street supply more unpredictable and deadly.
Driven by low cost, ease of manufacture, and high profitability, organized criminal suppliers have saturated the market with these deadly drugs, forcing the medical profession to rethink its clinical calculus on opioid addiction and treatment.
Methadone and buprenorphine remain the standard, first-line treatments for opioid-use disorder. These are long-acting drugs that don’t deliver the sharp high of opioids but stop cravings and withdrawal over time in a graduated fashion with a primary goal of treatment and recovery. But these conventional opioid agonist therapy (OAT) treatments were developed for a different era, when heroin and morphine dominated the illicit drug supply. They do not always work for people exposed to the much more potent and unpredictable fentanyl supply, which can often contain traces of other street drugs.
Within this context, Safer Opioid Supply (SOS) emerged to meet this new reality.
Health Canada defines it as providing prescribed medications as a safer alternative to the toxic illegal drug supply. In selected, closely supervised cases, providing a pharmaceutical‑grade opioid under medical oversight can prevent overdose, reduce ER visits, and create the clinical stability needed for engagement with housing, mental health, and vocational supports. Unfortunately, not all safer supply programs have been created equal: poor standardization and a lack of appropriate safeguards in its design and rollout are at the heart of the highly charged debate over its effectiveness. There have been well-documented problems with diversion, lax prescribing practices, and an unfortunate overemphasis by policymakers on the “harm reduction” pillar of addiction medicine that prioritizes stabilizing addicts and preventing death, without adequately offering access to therapies aimed at long-term recovery.
But when done right, safer supply can be effective and is entirely distinct from supervised consumption sites. SOS involves medically prescribed, regulated substances delivered within a structured clinical program; supervised consumption sites enable supervised use of one’s own illicit supply. Each has a different objective and risk profile, and conflating the two only adds to the confusion among Canadians and policymakers alike.
In clinics with high-quality treatment programs, safer supply is not an automatic take-home prescription and it is not delivered as a stand-alone transaction. Entry follows a comprehensive assessment of opioid-use history, overdose risk, medical and psychiatric comorbidities, previous treatments, and the patient’s goals. OAT is the default treatment offered and, where accepted, optimized. Patients take long-acting drugs to reduce cravings and remain in an ongoing therapeutic relationship with documented follow-up, rather than simply given drugs without ongoing monitoring. How often patients receive their medication, and how often they take it under supervision, should depend on their stability and the risk of the medication being diverted to the illicit supply.
Toxicology, prescription-monitoring data, and direct pharmacy communication are strategies that should be used to ensure safety and confirm that the plan is functioning as intended. If there are signs that patients aren’t taking their medication, are selling or sharing it, are becoming increasingly intoxicated, or are otherwise using it unsafely, doctors should respond by increasing oversight or changing the treatment, not simply cutting the patients off. Doing so risks pushing the patients back to the illicit drug supply and increasing their risk of overdose.
There is a fine line between laxity and flexibility in treatment to respond to patients’ unique needs. For example, there are several reasons why a patient’s urine sample might show continued traces of illicit drugs. Perhaps the prescribed dose or formulation is inadequate, or another treatment is needed, or that the patient is not taking the medication. Automatically discharging the patient from the program is not the answer. The goal should be to make diversion difficult and detectable while preserving a realistic path into OAT and the other wraparound supports like mental healthcare or housing and recovery-oriented services as needed.
Emerging evidence and surveillance suggest that responsibly implemented SOS can reduce acute harms. National surveillance shows declines in some opioid‑related harms in recent reporting periods. A 2025 study in The Lancet Public Health reported that prescribed SOS programs in Ontario were associated with significant reductions in emergency department visits, hospitalizations, and incident infections among people at high risk of overdose — findings consistent with frontline clinical reports that SOS stabilizes patients and reduces acute morbidity.
However, SOS is not a universal remedy; the model advocated here is a narrowly targeted, physician‑led clinical intervention for a subset of patients — those at high risk of overdose for whom first‑line opioid‑agonist therapies (OAT) have failed. It is a bridge to treatment and reintegration rather than an end state of maintenance without recovery goals.
Policy should therefore protect regulated, accountable SOS as one tool in a recovery continuum while insisting on rigorous standards, oversight, and wraparound supports.
In its new policy, the College of Physicians and Surgeons of Ontario (CPSO) now requires an in-person comprehensive assessment before initiating or continuing safer-supply prescribing, an OAT offer, and in-person reassessment at least every three months. It recognizes daily or observed dispensing as a risk-mitigation measure, while also requiring an ongoing therapeutic relationship and appropriate monitoring.
To retain public trust and clinical integrity, SOS must operate under enforceable, consistent standards:
- Rigorous eligibility and assessment: Patients should receive a comprehensive in-person assessment and regular reassessment covering overdose risk, previous OAT experience, comorbidities and treatment goals. This limits SOS to appropriate high-risk patients and ensures continuing clinical oversight, consistent with the recently changed CPSO requirements.
- Risk-based medication and dispensing: Formulation, dose, dispensing frequency and observed dosing should reflect each patient’s stability and diversion risk. This preserves clinical flexibility while limiting stockpiling, theft, and resale.
- Monitoring with a graduated response: Programs should use toxicology, medication histories, pharmacy records, and systems such as the Narcotics Monitoring System and Connecting Ontario, the province’s real-time digital record system. Monitoring makes unsafe use or diversion detectable and supports proportionate intervention rather than indifference or abrupt discharge.
- An integrated care pathway: SOS should connect patients with OAT, primary and mental-health care, housing, treatment, and employment supports. These connections turn short-term stabilization into a credible opportunity for recovery.
- Measurement of community impacts: Programs should record substantiated concerns involving diversion, discarded medication, public intoxication, and neighbourhood disorder. This ensures that patient benefits are evaluated alongside possible harms to the surrounding community.
These elements protect both patients and neighbours and make diversion both more difficult and more detectable. Regulatory bodies (e.g., provincial Colleges of Physicians/Pharmacists) across the country can and should make these standards mandatory and enforceable, with the appropriate variation based on local circumstances.
These types of policies have already been implemented with positive effects. For example, Alberta has intentionally narrowed the institutional settings for high‑potency prescribed alternatives through a licensing framework for Narcotic Transition Services (NTS). That framework requires licensing, clinical oversight by addiction‑medicine physicians, individualized treatment plans, reporting mechanisms, and a preference for delivery within regional or provincial health authorities except where explicit exemptions apply. The policy’s objective is to concentrate high‑risk prescribing in tightly governed sites with mandated transition pathways to evidence‑based OAT and recovery supports.
That said, the Alberta model illustrates a trade-off: greater central control and standardized quality on one hand, and reduced private provision, clinician flexibility, and potentially narrower geographic or temporal access on the other. Policymakers must choose whether centralization or regulated private provision better balances rapid access, clinical innovation, local responsiveness, and accountability.
Safer supply must be a bridge to services that address the social determinants of addiction. Clinical stabilization without funded wrap‑around supports — housing, intensive mental health care, employment programs, and inpatient treatment capacity where indicated — risks turning SOS into long‑term dependency maintenance. Governments must fund and coordinate these complementary services if SOS is to achieve recovery outcomes rather than prolonged stabilization.
To reconcile access, safety, and public confidence, policymakers should adopt core, enforceable reforms:
- Harmonized minimum standards. Provinces should establish a common floor for eligibility, assessment, dispensing, monitoring, and documentation. This prevents major differences in safety and quality across jurisdictions.
- Inspection, reporting, and proportionate sanctions. Programs should be open to audits, critical-incident reporting and corrective-action requirements, following principles found in Alberta’s licensing framework. Enforcement ensures that standards have practical consequences.
- Funded recovery capacity. Governments should fund housing, counselling, psychiatric care, inpatient and outpatient treatment, and employment supports. Without accessible services, SOS cannot function as a meaningful bridge to recovery.
- Independent and transparent evaluation. Programs should be funded to publish standardized results covering overdose, mortality, treatment retention and transitions, diversion, housing stability, and community impacts. Comparable data allow effective programs to be distinguished from poorly governed ones.
A comprehensive approach, aimed at recovery
The politics of safer supply shape institutional choices. Conservatives understandably recoil at the optics of prescribing opioids; the political instinct is to restore drug‑free public spaces and to resist policies that appear to normalize use. Progressives, focused on access and harm reduction, often favour more expansive, state‑delivered options that often veer into destigmatization of unhealthy activities, though are rightly concerned with removing barriers to care.
This is not abstract for me. I have advocated publicly for improved safer-supply standards and have seen first-hand why consistency matters. Beyond the College’s 2026 changes, provinces should invest in recovery-oriented capacity. Alberta reports adding more than 10,000 publicly funded treatment spaces and is building recovery communities offering long-term residential care, counselling, OAT, employment training, and housing and financial supports. Those investments must themselves be independently evaluated, but they demonstrate the scale and breadth of services we should be prepared to build.
Nor should the public-versus-private question become a proxy for the substantive debate. Public delivery can standardize care and absorb complex patients, but it can also become centralized and difficult to access. Private providers can expand capacity and respond locally. Individual clinicians remain subject to professional discipline in either setting. The best settlement is plural delivery under one uncompromising accountability framework that is consistent for all providers.
Safer supply, properly targeted and rigorously regulated, can be a pragmatic response to the new realities of today’s illicit-drug market. It can reduce acute harm for selected high-risk patients and create clinical stability from which treatment and recovery become possible. Poorly assessed, lightly monitored prescribing can instead enable diversion, obscure whether the patient is benefiting and erode public confidence.
The task is therefore to separate credible clinical care from careless prescribing. OAT should remain the first-line treatment, with SOS reserved for selected high-risk patients, while rigorous and consistent standards are put in place alongside the private and public investments needed to make mental-health and recovery-oriented treatment capacity a genuine reality.
David D’Souza MD CCFP DTM&H DCAPM FCFP is an addictions and pain medicine physician, and assistant professor at Queen’s University and Toronto Metropolitan University. He started New Dawn Medical, a multidisciplinary network of clinics specializing in treatment of outpatient substance use disorders.
